Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Medtronic to submit first module of US approval application for novel peripheral angioplasty device to FDA

Medtronic : 04 June, 2013  (Company News)
Medtronic declares that enough patients have been enrolled in the company's clinical studies of the IN.PACT Admiral drug-eluting balloon to support the company's US regulatory approval submission of the novel angioplasty device, which is designed to treat atherosclerotic lesions in the superficial femoral artery.

In a related development, Medtronic also announced today that it plans to submit the first module of the pre-market approval (PMA) application for the IN.PACT Admiral drug-eluting balloon to the USA. Food and Drug Administration (FDA) over the summer.

"The IN.PACT Admiral drug-eluting balloon represents a novel angioplasty device from Medtronic that we foresee launching in the United States in late 2015, pending FDA approval," said Tony Semedo, president of Medtronic's Endovascular Therapies business. "It targets atherosclerotic lesions in the superficial femoral artery with a treatment modality that aims to deliver an anti-restenotic drug while leaving nothing behind."

More than 1,000 patients have been enrolled in the IN.PACT SFA I, II, II pharmacokinetics (PK) and Global studies to date. Clinical data from these studies will comprise a significant portion of Medtronic's PMA application to the FDA for the IN.PACT Admiral drug-eluting balloon. IN.PACT SFA I is a European study; IN.PACT SFA II and II PK, both US studies; and IN.PACT Global, an international study being conducted outside the United States.

The ongoing global IN.PACT clinical program includes 29 studies involving more than 4,600 patients at approximately 230 sites worldwide. Through these company-sponsored and physician-initiated studies, Medtronic's portfolio of IN.PACT drug-eluting balloons will be investigated thoroughly for the treatment of arterial disease in a variety of vessel beds. As part of this programme, Medtronic is currently enrolling the IN.PACT Global study, a first-of-its-kind, 'real-world' evaluation of the company's IN.PACT drug-eluting balloons involving 1,500 patients with femoropopliteal lesions of any length at up to 80 sites worldwide.

IN.PACT drug-eluting balloons feature a proprietary coating called FreePac that is a formulation of paclitaxel and urea, an excipient that facilitates absorption of the drug into the vessel wall. They received the CE mark in 2008 and 2009 and are available in many countries around the world.

In the United States, the IN.PACT Admiral drug-eluting balloon is limited to investigational use under an investigational device exemption (IDE) granted by the FDA and, like every drug-eluting balloon, is not yet commercially available.

The superficial femoral artery (SFA) runs close to the surface of the upper leg, from the groin to the knee. As a result of its location, the SFA experiences a variety of torsion and compression forces that pose inherent challenges with the use of permanent metallic stents in the treatment of atherosclerosis, which causes the body's arteries to narrow with the accumulation of fatty deposits (called plaque) inside them.


Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo